成人网站免费看黄a站视频,免费久久精品国产片,国产视频不卡一区二区三区

Liguzinediol

NMR下載 COA and HPLC MSDS下載
names：
3,6-Dimethyl-2,5-pyrazinedimethanol
CAS號：
909708-65-2
MDL Number：
MF(分子式)： C8H12N2O2 MW(分子量)： 168.196
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	Liguzinediol
英文別名	Liguzinediol
CAS號	909708-65-2
Inchi	InChI=1S/C8H12N2O2/c1-5-7(3-11)10-6(2)8(4-12)9-5/h11-12H,3-4H2,1-2H3
InchiKey	DLCVYRQRINMKBM-UHFFFAOYSA-N
分子式 Formula	C8H12N2O2
分子量 Molecular Weight	168.196
溶解度Solubility
性狀	Solid powder
儲藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說明	Liguzinediol(CAS:909708-65-2):僅限應(yīng)用于工業(yè)或者科學研究過程中非醫(yī)療目的，不應(yīng)用于人類或動物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。
Introduction	Liguzinediol is a potent positive inotropic agent, inhibiting myocardial cell apoptosis.
Application1
Application2
Application3

警示圖
危險性	Warning
危險性警示
安全聲明
安全防護
備注

[1]Li S, Huang H, Zhang M, Wang W, Xue S, Gao Y, Xie M, Chen K, Liu F, Chen L. Liguzinediol Enhances the Inotropic Effect of Rat Hearts via Inhibition of Protein Phosphatase (PP1 and PP2A) Activities. J Cardiovasc Pharmacol. 2017 Apr;69(4):236-244. doi: 10.1097/FJC.0000000000000467. PubMed PMID: 28134629.

[2]Wu X, Qi X, Lu Y, Lin C, Yuan Y, Zhu Q, Yin Q, Li W, Li Y, Bian H. Liguzinediol protects against cardiac fibrosis in rats in vivo and in vitro. Biomed Pharmacother. 2016 May;80:260-7. doi: 10.1016/j.biopha.2016.03.033. Epub 2016 Apr 1. PubMed PMID: 27133065.

[3] Zhu HH, Chen YQ, Cheng D, Li W, Wang TL, Wen HM, Chen L, Liu J. Synthesis and positive inotropic activity evaluation of liguzinediol metabolites. Bioorg Med Chem Lett. 2016 Feb 1;26(3):882-884. doi: 10.1016/j.bmcl.2015.12.072. Epub 2015 Dec 21. PubMed PMID: 26725025.

[4] Cheng D, Zhou Y, Li W, Shan CX, Chai C, Cui XB, Kang B, Wang TL, Wen HM. Identification, Characterization, Synthesis and Quantification of Related Impurities of Liguzinediol. J Chromatogr Sci. 2015 Sep;53(8):1280-8. doi: 10.1093/chromsci/bmu230. Epub 2015 Feb 12. PubMed PMID: 25680683.

[5] Zhang J, Li W, Wen HM, Zhu HH, Wang TL, Cheng D, Yang KD, Chen YQ. Synthesis and biological evaluation of liguzinediol mono- and dual ester prodrugs as promising inotropic agents. Molecules. 2014 Nov 5;19(11):18057-72. doi: 10.3390/molecules191118057. PubMed PMID: 25379643.

6: Li Y, Song P, Zhu Q, Yin QY, Ji JW, Li W, Bian HM. Liguzinediol improved the heart function and inhibited myocardial cell apoptosis in rats with heart failure. Acta Pharmacol Sin. 2014 Oct;35(10):1257-64. doi: 10.1038/aps.2014.75. Epub 2014 Sep 15. PubMed PMID: 25220638; PubMed Central PMCID: PMC4186991.7: Shan CX, Li W, Wen HM, Wang XZ, Zhu XW, Cui XB. Metabolite identification of liguzinediol in dogs by ultra-flow liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Sep 15;967:63-8. doi: 10.1016/j.jchromb.2014.06.029. Epub 2014 Jul 5. PubMed PMID: 25078861.8: Liu Z, Li W, Qin K, Wen K, Zhu CJ, Li NG, Bian HM, Wen HM, Chen L. Scaffold evaluation of liguzinediol analogs as novel cardiotonic agents. Pharmazie. 2013 Dec;68(12):926-32. PubMed PMID: 24400437.9: Liu Z, Li W, Wen HM, Bian HM, Zhang J, Chen L, Chen L, Yang KD. Synthesis, biological evaluation, and pharmacokinetic study of novel liguzinediol prodrugs. Molecules. 2013 Apr 18;18(4):4561-72. doi: 10.3390/molecules18044561. PubMed PMID: 23599014.10: Chen L, Xu Y, Li W, Wu H, Luo Z, Li X, Huang F, Young C, Liu Z, Zhou S. The novel compound liguzinediol exerts positive inotropic effects in isolated rat heart via sarcoplasmic reticulum Ca2+ ATPase-dependent mechanism. Life Sci. 2012 Oct 5;91(11-12):402-408. doi: 10.1016/j.lfs.2012.08.001. Epub 2012 Aug 11. PubMed PMID: 22906633.1

對不起，暫無產(chǎn)品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開